NASDAQ · AKTS
Aktis Oncology, Inc.
$16.85+$0.03 (+0.18%)
Aktis Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.72% below the high.
Loading market information…
NASDAQ · DRTS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Alpha Tau Medical Ltd’s quoted price sits in the upper half of its reported 52-week range, 16.21% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Alpha Tau Medical Ltd’s next earnings report is currently expected on Nov 19, 2026, with estimated earnings per share of -$0.14. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alpha Tau Medical Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.12+14.29% vs estimate |
| $0.00-100.0% vs estimate |
| Q4 2024 | Mar 12, 2025 | -$0.130.0% vs estimate | $0.00 |
|---|
| Q2 2024 | Aug 14, 2024 | -$0.11+15.38% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $16.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$16.85+$0.03 (+0.18%)
Aktis Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.72% below the high.
$13.51+$0.14 (+1.05%)
InMode Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.96% below the high.
$3.12+$0.02 (+0.65%)
Entera Bio Ltd.’s quoted price sits in the upper half of its reported 52-week range, 25.71% below the high.
$68.66+$0.48 (+0.7%)
Sol-Gel Technologies Ltd.’s quoted price sits in the upper half of its reported 52-week range, 29.92% below the high.
$13.86+$0.30 (+2.21%)
MediWound Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.64% below the high.
$1.17-$0.08 (-6.02%)
Perspective Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.01% below the high.
$5.59-$0.19 (-3.29%)
PolyPid Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.28% below the high.
HK$1.78-HK$0.02 (-0.84%)
Sisram Medical Ltd’s quoted price sits in the lower half of its reported 52-week range, 63.75% below the high.
